- 5 Results
Lowest price: € 16.20, highest price: € 111.22, average price: € 68.15
1
Indacaterol | The First Once-daily Long-acting Beta2 Agonist for COPD | Alexandre Trifilieff | Buch | Milestones in Drug Therapy | HC runder Rücken kaschiert | VII | Englisch | 2013 | Springer Basel - Trifilieff, Alexandre
Order
at booklooker.de
€ 94.40
Shipment: € 0.001
OrderSponsored link
Trifilieff, Alexandre:

Indacaterol | The First Once-daily Long-acting Beta2 Agonist for COPD | Alexandre Trifilieff | Buch | Milestones in Drug Therapy | HC runder Rücken kaschiert | VII | Englisch | 2013 | Springer Basel - hardcover

2013, ISBN: 9783034807081

[ED: Gebunden], [PU: Springer Basel], Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an … More...

Shipping costs:Versandkostenfrei, Versand nach Deutschland. (EUR 0.00) preigu
2
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy)
Order
at Amazon.de (Intern. Bücher)
€ 100.92
Shipment: € 3.001
OrderSponsored link
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy) - hardcover

2013, ISBN: 9783034807081

Springer, Gebundene Ausgabe, Auflage: 2014, 153 Seiten, Publiziert: 2013-11-27T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 20 black & white illustrations, 21 colou, 7.97 kg, Pharmakol… More...

Shipping costs:Die angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00)
3
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy)
Order
at Amazon.de (Intern. Bücher)
€ 16.20
Shipment: € 3.001
OrderSponsored link
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy) - hardcover

2013

ISBN: 9783034807081

Springer, Gebundene Ausgabe, Auflage: 2014, 153 Seiten, Publiziert: 2013-11-27T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 20 black & white illustrations, 21 colou, 7.97 kg, Pharmakol… More...

Shipping costs:Auf Lager. Die angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00) lange_und_springer_antiquariat
4
Order
at AbeBooks.de
€ 18.00
Shipment: € 3.001
OrderSponsored link
Trifilieff, Alexandre (Ed.):
Indacaterol. The First Once-daily Long-acting Beta2 Agonist for COPD. - hardcover

2014, ISBN: 3034807082

[EAN: 9783034807081], [PU: Basel, Birkhäuser Verlag.], METZLER, 235 mm x 155 mm. VII, 146 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, … More...

Shipping costs: EUR 3.00 Antiquariat im Hufelandhaus GmbH vormals Lange & Springer, Berlin, Germany [2726420] [Rating: 5 (von 5)]
5
Indacaterol The First Once-daily Long-acting Beta2 Agonist for COPD - Trifilieff, Alexandre (Herausgeber)
Order
at Achtung-Buecher.de
€ 111.22
Shipment: € 0.001
OrderSponsored link
Trifilieff, Alexandre (Herausgeber):
Indacaterol The First Once-daily Long-acting Beta2 Agonist for COPD - hardcover

2013, ISBN: 3034807082

2014 Gebundene Ausgabe Pharmakologie, Asthma; Beta-2-Agonists; Bronchitis; Bronchodilatator; lungfunction, mit Schutzumschlag 11, [PU:Springer Basel; Springer Basel AG]

Shipping costs:Versandkostenfrei innerhalb der BRD. (EUR 0.00) MARZIES.de Buch- und Medienhandel, 14621 Schönwalde-Glien

1As some platforms do not transmit shipping conditions to us and these may depend on the country of delivery, the purchase price, the weight and size of the item, a possible membership of the platform, a direct delivery by the platform or via a third-party provider (Marketplace), etc., it is possible that the shipping costs indicated by euro-book.co.uk / euro-book.co.uk do not correspond to those of the offering platform.

Bibliographic data of the best matching book

Details of the book
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy)

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled ss2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Details of the book - Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy)


EAN (ISBN-13): 9783034807081
ISBN (ISBN-10): 3034807082
Hardcover
Publishing year: 2014
Publisher: Trifilieff, Alexandre, Springer

Book in our database since 2014-09-14T17:56:16+01:00 (London)
Detail page last modified on 2023-12-18T11:29:41+00:00 (London)
ISBN/EAN: 9783034807081

ISBN - alternate spelling:
3-0348-0708-2, 978-3-0348-0708-1
Alternate spelling and related search-keywords:
Book author: alexandre, basel iii
Book title: acting first six, copd, milestones


Information from Publisher

Author: Alexandre Trifilieff
Title: Milestones in Drug Therapy; Indacaterol - The First Once-daily Long-acting Beta2 Agonist for COPD
Publisher: Springer; Springer Basel
146 Pages
Publishing year: 2013-11-27
Basel; CH
Printed / Made in
Weight: 3,613 kg
Language: English
106,99 € (DE)
109,99 € (AT)
118,00 CHF (CH)
POD
VII, 146 p. 41 illus., 21 illus. in color.

BB; Pharmacology/Toxicology; Hardcover, Softcover / Medizin/Pharmazie; Pharmakologie; Verstehen; Asthma; Beta-2-Agonists; Bronchitis; Bronchodilatator; Lung function; Pneumology/Respiratory System; Pharmacology; Pneumology; Lungen- und Bronchialheilkunde; EA

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Current Pharmacotherapy for COPD.- The preclinical pharmacology of indacaterol.- The design of the indacaterol molecule.- The early clinical development of Indacaterol.- INHANCE: An adaptive confirmatory study with dose selection at interim.- Phase III clinical efficacy studies – lung function.- Phase III Clinical Efficacy of Indacaterol.- Patient-centered Outcomes.- The history and performance of the Breezhaler device.- What does the future hold for the therapy of COPD?  

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Summarizes preclinical and clinical data

A valuable source of information for scientists and clinicians

Contemporary monograph on the pharmacotherapy of COPD

Includes supplementary material: sn.pub/extras



More/other books that might be very similar to this book

Latest similar book:
9783034807098 Indacaterol (Alexandre Trifilieff)


< to archive...